DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Loibl S, OʼShaughnessy J, Untch M. et al.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess). A randomised, phase 3 trial.
Lancet Oncol 2018;
19: 497-509
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.